BACKGROUND: Human, animal and cell models support a role for pesticides in the etiology of Parkinson disease. Susceptibility to pesticides may be modified by genetic variants of xenobiotic enzymes, such as paraoxonase, that play a role in metabolizing some organophosphates. METHODS: We examined associations between Parkinson disease and the organophosphates diazinon, chlorpyrifos, and parathion, and the influence of a functional polymorphism at position 55 in the coding region of the PON1 gene (PON1-55). From 1 January 2001 through 1 January 2008, we recruited 351 incident cases and 363 controls from 3 rural California counties in a population-based case-control study. Participants provided a DNA sample, and residential exposure to organophosphates was determined from pesticide usage reports and a geographic information system (GIS) approach. We assessed the main effects of both genes and pesticides in unconditional logistic regression analyses, and evaluated the effect of carrying a PON1-55 MM variant on estimates of effects for diazinon, chlorpyrifos, and parathion exposures. RESULTS: Carriers of the variant MM PON1-55 genotype exposed to organophosphates exhibited a greater than 2-fold increase in Parkinson disease risk compared with persons who had the wildtype or heterozygous genotype and no exposure (for diazinon, odds ratio = 2.2 [95% confidence interval = 1.1-4.5]; for chlorpyrifos, 2.6 [1.3-5.4]). The effect estimate for chlorpyrifos, was more pronounced in younger-onset cases and controls (<or=60 years) (5.3 [1.7-16]). No increase in risk was noted for parathion. CONCLUSION: The increase in risk we observed among PON1-55 variant carriers for specific organophosphates metabolized by PON1 underscores the importance of considering susceptibility factors when studying environmental exposures in Parkinson disease.
BACKGROUND:Human, animal and cell models support a role for pesticides in the etiology of Parkinson disease. Susceptibility to pesticides may be modified by genetic variants of xenobiotic enzymes, such as paraoxonase, that play a role in metabolizing some organophosphates. METHODS: We examined associations between Parkinson disease and the organophosphatesdiazinon, chlorpyrifos, and parathion, and the influence of a functional polymorphism at position 55 in the coding region of the PON1 gene (PON1-55). From 1 January 2001 through 1 January 2008, we recruited 351 incident cases and 363 controls from 3 rural California counties in a population-based case-control study. Participants provided a DNA sample, and residential exposure to organophosphates was determined from pesticide usage reports and a geographic information system (GIS) approach. We assessed the main effects of both genes and pesticides in unconditional logistic regression analyses, and evaluated the effect of carrying a PON1-55 MM variant on estimates of effects for diazinon, chlorpyrifos, and parathion exposures. RESULTS: Carriers of the variant MM PON1-55 genotype exposed to organophosphates exhibited a greater than 2-fold increase in Parkinson disease risk compared with persons who had the wildtype or heterozygous genotype and no exposure (for diazinon, odds ratio = 2.2 [95% confidence interval = 1.1-4.5]; for chlorpyrifos, 2.6 [1.3-5.4]). The effect estimate for chlorpyrifos, was more pronounced in younger-onset cases and controls (<or=60 years) (5.3 [1.7-16]). No increase in risk was noted for parathion. CONCLUSION: The increase in risk we observed among PON1-55 variant carriers for specific organophosphates metabolized by PON1 underscores the importance of considering susceptibility factors when studying environmental exposures in Parkinson disease.
Authors: Jane A McElroy; Patrick L Remington; Amy Trentham-Dietz; Stephanie A Robert; Polly A Newcomb Journal: Epidemiology Date: 2003-07 Impact factor: 4.822
Authors: S N Kelada; P Costa-Mallen; H Checkoway; H A Viernes; F M Farin; T Smith-Weller; G M Franklin; L G Costa; W T Longstreth; C E Furlong; G P Jarvik; P D Swanson Journal: J Neurol Neurosurg Psychiatry Date: 2003-04 Impact factor: 10.154
Authors: Jordi Clarimon; Johanna Eerola; Olli Hellström; Pentti J Tienari; Andrew Singleton Journal: Neurosci Lett Date: 2004-09-02 Impact factor: 3.046
Authors: Mona Thiruchelvam; Alison McCormack; Eric K Richfield; Raymond B Baggs; A William Tank; Donato A Di Monte; Deborah A Cory-Slechta Journal: Eur J Neurosci Date: 2003-08 Impact factor: 3.386
Authors: Daniel W Goldberg; John P Wilson; Craig A Knoblock; Beate Ritz; Myles G Cockburn Journal: Int J Health Geogr Date: 2008-11-26 Impact factor: 3.918
Authors: F D Dick; G De Palma; A Ahmadi; A Osborne; N W Scott; G J Prescott; J Bennett; S Semple; S Dick; P Mozzoni; N Haites; S Bezzina Wettinger; A Mutti; M Otelea; A Seaton; P Soderkvist; A Felice Journal: Occup Environ Med Date: 2007-04-20 Impact factor: 4.402
Authors: L Brighina; R Frigerio; N K Schneider; T G Lesnick; M de Andrade; J M Cunningham; M J Farrer; S J Lincoln; H Checkoway; W A Rocca; D M Maraganore Journal: Neurology Date: 2008-03-05 Impact factor: 9.910
Authors: Dana B Hancock; Eden R Martin; Gregory M Mayhew; Jeffrey M Stajich; Rita Jewett; Mark A Stacy; Burton L Scott; Jeffery M Vance; William K Scott Journal: BMC Neurol Date: 2008-03-28 Impact factor: 2.474
Authors: Rekek Negga; David A Rudd; Nathan S Davis; Amanda N Justice; Holly E Hatfield; Ana L Valente; Anthony S Fields; Vanessa A Fitsanakis Journal: Neurotoxicology Date: 2011-03-03 Impact factor: 4.294
Authors: Haley E Speed; Cory A Blaiss; Ahleum Kim; Michael E Haws; Neal R Melvin; Michael Jennings; Amelia J Eisch; Craig M Powell Journal: Toxicol Sci Date: 2011-09-26 Impact factor: 4.849
Authors: Judy K Qiang; Yvette C Wong; Andrew Siderowf; Howard I Hurtig; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Dora Yearout; James B Leverenz; Thomas J Montine; Matt Stern; Susan Mendick; Danna Jennings; Cyrus Zabetian; Ken Marek; Alice S Chen-Plotkin Journal: Ann Neurol Date: 2013-08-06 Impact factor: 10.422
Authors: Samuel M Goldman; Freya Kamel; G Webster Ross; Grace S Bhudhikanok; Jane A Hoppin; Monica Korell; Connie Marras; Cheryl Meng; David M Umbach; Meike Kasten; Anabel R Chade; Kathleen Comyns; Marie B Richards; Dale P Sandler; Aaron Blair; J William Langston; Caroline M Tanner Journal: Mov Disord Date: 2012-10-08 Impact factor: 10.338